ライフサイエンスコーパス: angiotensin receptor

1 cal angiotensin II production and the type 2 angiotensin receptor.

2 asoconstriction via the activation of type 1 angiotensin receptors.

3 (2)-adrenergic) and G(alpha)(q)-coupled (AT1 angiotensin) receptors.

4 rphisms (SNPs) in the angiotensinogen (AGT), angiotensin receptor 1 (AGTR1), and angiotensin receptor

5 n (AGT), angiotensin receptor 1 (AGTR1), and angiotensin receptor 2 (AGTR2) genes were evaluated for

6 ytometric analysis and Western blot revealed angiotensin receptor 2 (AT(2)) expression in T and NK ce

7 BKB2R(-/-) mice have increased angiotensin receptor 2 (AT2R) mRNA and protein expressio

8 ing from elevated angiotensin II (AngII) and angiotensin receptor 2 (AT2R) producing increased plasma

9 1)-AA), stimulates sEng production via AT(1) angiotensin receptor activation in pregnant mice but not

10 the disease result from autoantibody-induced angiotensin receptor activation.

11 covered that a circulating autoantibody, the angiotensin receptor agonistic autoantibody (AT(1)-AA),

12 rials, however, suggested the benefit of the angiotensin receptor and angiotensin-converting enzyme b

13 c administration of specific blockers of the angiotensin receptor and the Na-Ca exchanger.

14 embranes, which is distinctly different from angiotensin receptors and key proteases processing angio

15 colleagues present evidence that implicates angiotensin receptors and the relocation of beta-catenin

16 tural basis of the distinct functions of the angiotensin receptors, and may guide the design of new s

17 Thus, angiotensin receptor antagonism by losartan has superior

18 f angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist (88.3% versus 86.6%), an

19 Thus, this combined angiotensin receptor antagonist and neprilysin inhibitor

20 ll three isoforms of TGF-beta), losartan (an angiotensin receptor antagonist), or a combination of th

21 Heart Failure) trial demonstrated that a new angiotensin receptor antagonist-neprilysin inhibitor was

22 gh) dose (>50%, n = 201), or those receiving angiotensin receptor antagonists (n = 51).

23 angiotensin converting enzyme inhibitors or angiotensin receptor antagonists in early life can preve

24 ay lead to the development of a new class of angiotensin receptor antagonists with activities biased

25 rs, calcium channel blockers, diuretics, and angiotensin receptor antagonists), smoking status, alcoh

26 stem inhibition with dual blockade, ACEI and angiotensin receptor antagonists, on renal volume and ki

27 of angiotensin-converting enzyme inhibitors/angiotensin receptor antagonists, use of beta-blocker, a

28 Recently angiotensin receptor AT(2)R has been associated negative

29 n and termination of signaling of the type I angiotensin receptor (AT(1)-R) can lead to dynamic chang

30 genic autoantibodies that activate the major angiotensin receptor, AT(1).

31 Biased agonism on the type I angiotensin receptor (AT1-R) can achieve different outco

32 ampsia have autoantibodies that activate the angiotensin receptor, AT1, and that autoantibody-mediate

33 r (lpr) mice lacking the major murine type 1 angiotensin receptor (AT1A); lpr mice develop a generali

34 of beta-arrestins in cross-talk between the angiotensin receptor (AT1aR) and a member of the transie

35 beta-arrestin2 recruitment to unliganded AT1 angiotensin receptor (AT1R).

36 ange from time 0 to 180 min; the response to angiotensin receptor blockade (ARB) was defined as the c

37 Angiotensin receptor blockade and inhibition of local An

38 odocytes, which was prevented by concomitant angiotensin receptor blockade application and TRPC6 knoc

39 hat inhibition of TGF-beta signaling through angiotensin receptor blockade can attenuate CS-induced l

40 Little is known about whether direct angiotensin receptor blockade can reduce atherosclerosis

41 erglycemia and the antiproteinuric effect of angiotensin receptor blockade or angiotensin-converting

42 injections (RR 0.45; 95% CI 0.24-0.83), and angiotensin receptor blockade vs placebo (RR 0.65; 95% C

43 ous angiotensin II test showed that complete angiotensin receptor blockade was achieved only in the h

44 to pharmacological reduction of fibrosis by angiotensin receptor blockade.

45 combination therapy with NEP-inhibitors and angiotensin-receptor-blockade, which has been shown bein

46 ]: 1.04 to 1.10) and discharge ACE inhibitor/angiotensin receptor blocker (ARB) in LV dysfunction (64

47 tensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) on atherosclerotic ev

48 The combination of a diuretic and an angiotensin receptor blocker (ARB) or angiotensin-conver

49 ensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) should be used for se

50 ed in increased cancer risk, with a focus on angiotensin receptor blocker (ARB) therapy, as recent pu

51 giotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) use and mortality in

52 otensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) use, ESA use, dialysi

53 sing angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (beta=0.36, P<0.001; CI: 0.

54 : high dose, 0.55; low dose, 0.72; both ACEi/angiotensin receptor blocker and beta-blocker: high dose

55 ate, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and oral anti-diabetic agen

56 Telmisartan, an angiotensin receptor blocker and partial PPAR-gamma agon

57 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker at discharge, have little r

58 g angiotensin converting enzyme inhibitor or angiotensin receptor blocker background therapy.

59 ) administration of ultrahigh dosages of the angiotensin receptor blocker candesartan on the progress

60 clinical trial, comparing the effects of the angiotensin receptor blocker candesartan with placebo in

61 The angiotensin receptor blocker component of LCZ696, valsar

62 ted, whereas acute HF and patients receiving angiotensin receptor blocker had higher plasma Ang II wi

63 been demonstrated that Valsartan (Val) as an angiotensin receptor blocker has renoprotective effects,

64 uggest that aliskiren was as effective as an angiotensin receptor blocker in attenuating this measure

65 r angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in eligible patients.

66 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in persons with CKD to impr

67 Treatment for 4 weeks with the angiotensin receptor blocker irbesartan, but not with th

68 The angiotensin receptor blocker losartan was given to half

69 Combined angiotensin receptor blocker neprilysin inhibitors (ARNI

70 ng the effects of aliskiren combined with an angiotensin receptor blocker on intermediate markers of

71 etermine the effects of pretreatment with an angiotensin receptor blocker on left ventricular (LV) fu

72 giotensin receptor neprilysin inhibitor with angiotensin receptor blocker on Management Of heart fail

73 ting the renoprotective benefit of adding an angiotensin receptor blocker or a mineralocorticoid rece

74 e of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or beta-blocker and 60- to

75 eive angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy (P<0.01).

76 from the combination of an ACE-inhibitor and angiotensin receptor blocker therapy in patients with va

77 giotensin-converting enzyme inhibitor and/or angiotensin receptor blocker therapy is the standard of

78 angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy on patients who hav

79 d angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 100% beta-blocker

80 d angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 35% beta-blocker t

81 d angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 51% beta-blocker t

82 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker throughout the study.

83 Angiotensin receptor blocker treatment may blunt the har

84 nd to identify patients who can benefit from angiotensin receptor blocker treatment.

85 of associations and to explore the impact of angiotensin receptor blocker treatment.

86 Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker uptake increased from 46% t

87 r angiotensin-converting enzyme inhibitor or angiotensin receptor blocker usage during continuous flo

88 d angiotensin converting enzyme inhibitor or angiotensin receptor blocker usage were not significantl

89 y angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use at discharge was associ

90 .5%, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use in 24.9+/-1.9%, and asp

91 and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use in patients with an Ame

92 s in angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use or anticoagulation for

93 , angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, and nonsmoking status-

94 Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, beta-blocker use, anti

95 and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use-is well suited to provi

96 were randomly assigned to receive either the angiotensin receptor blocker valsartan (titrated to 320

97 rketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan and the neprilysi

98 An angiotensin receptor blocker was administered at time 18

99 etic subjects not treated with ACE inhibitor/angiotensin receptor blocker who had the TT-ID-AA/AC gen

100 loped by scientists at Novartis, combines an angiotensin receptor blocker with a neprilysin inhibitor

101 angiotensin converting enzyme inhibitor, and angiotensin receptor blocker), and N-terminal probrain n

102 tensin-converting enzyme inhibitor (ACEi, or angiotensin receptor blocker), beta-blocker, or both dru

103 When given with an angiotensin receptor blocker, aliskiren produces signifi

104 osemide, diltiazem, aspirin, simvastatin, an angiotensin receptor blocker, and insulin.

105 We evaluated the ability of irbesartan, an angiotensin receptor blocker, and lipoic acid, an antiox

106 n patients receiving higher doses of ACEi or angiotensin receptor blocker, beta-blocker, or both (haz

107 an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker, o

108 DMT (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, or beta-blocker) at baseli

109 ngiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, should generally be includ

110 converting enzyme inhibitors or losartan, an angiotensin receptor blocker, will decrease the rate of

111 f angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

112 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

113 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

114 c agent that combines a NEP inhibitor and an angiotensin receptor blocker.

115 n either stand-alone neprilysin inhibitor or angiotensin receptor blocker.

116 and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.

117 rd ratio for eplerenone versus placebo, ACEi/angiotensin receptor blocker: high dose, 0.67; low dose,

118 tly less likely after dual treatment with an angiotensin-receptor blocker (ARB) and an angiotensin-co

119 otensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) for patients with lef

120 erting-enzyme inhibitor (lisinopril) plus an angiotensin-receptor blocker (telmisartan) or lisinopril

121 st orally active direct renin inhibitor, the angiotensin-receptor blocker losartan, and their combina

122 in-converting enzyme inhibitor) or losartan (angiotensin-receptor blocker) in FSGS mice stimulated th

123 ngiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker.

124 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (18.2% vs 16.9%, p = 1.000

125 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (66% versus 68%; P=0.04) a

126 1.73 m(-2)), greater renal vasodilation with angiotensin receptor blockers (approximately 145 mL x mi

127 ensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are generally well t

128 nsin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) doses on outcomes in

129 ensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) initiated after myoc

130 otensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), beta-blockers (BB),

131 ensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).

132 nin angiotensin system pathways suggest that angiotensin receptor blockers (ARBs) are ideal drugs to

133 nsin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are widely prescrib

134 nsin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are widely prescrib

135 The use of angiotensin receptor blockers (ARBs) correlates with red

136 ertensive patients (n = 469), patients using angiotensin receptor blockers (ARBs) did not show a decl

137 PURPOSE OF REVIEW: As their introduction, angiotensin receptor blockers (ARBs) have been widely pr

138 ensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) improves left ventr

139 tensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in patients with ty

140 ensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in preventing the n

141 Preclinical data suggest that angiotensin receptor blockers (ARBs) may have similar st

142 sin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) may increase the ri

143 in-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) on the composite of

144 iotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (

145 iotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, and

146 otensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), beta-blockers, and

147 target the renin angiotensin system, such as angiotensin receptor blockers (ARBs), have been associat

148 lyses assessed therapeutic substitution with angiotensin receptor blockers (ARBs).

149 tensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).

150 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (HR, 0.90; 95% CI, 0.79-1.

151 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ie, renin-angiotensin sys

152 itors (captopril, fosinopril, ramipril), and angiotensin receptor blockers (losartan, candesartan).

153 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartil

154 of angiotensin converting enzyme inhibitors/angiotensin receptor blockers (P = 0.02).

155 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (p = 0.029), higher biliru

156 ile lower ATP was associated with the use of angiotensin receptor blockers (P=0.015).

157 tensin-converting enzyme inhibitors [ACEIs], angiotensin receptor blockers [ARBs], and beta-blockers

158 nsin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and cilostazol) an

159 iotensin-converting enzyme inhibitors and/or angiotensin receptor blockers achieves only partial reno

160 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 82% were receiving bet

161 expression is ameliorated by antiproteinuric angiotensin receptor blockers and angiotensin-converting

162 ith angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers and an o

163 use angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers compared

164 Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers were pre

165 Angiotensin receptor blockers appear to be as effective

166 Angiotensin receptor blockers are renoprotective in hype

167 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers at admission), beta-blocke

168 of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers at discharge decreased in

169 f angiotensin-convering enzyme inhibitors or angiotensin receptor blockers during the study and a his

170 cardiovascular examples, such as the use of angiotensin receptor blockers for chronic heart failure,

171 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for secondary prevention a

172 (3) angiotensin-converting enzyme inhibitor/angiotensin receptor blockers for systolic dysfunction,

173 he therapeutic benefits of beta-blockers and angiotensin receptor blockers given the emerging concept

174 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers has become a crucial eleme

175 Specific benefits beyond those of other angiotensin receptor blockers have been claimed for tele

176 nd clinical data support the hypothesis that angiotensin receptor blockers have beneficial effects on

177 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have demonstrated benefici

178 vitro, specific actions not shared by other angiotensin receptor blockers have not yet been convinci

179 Thiazide diuretics, ACE-inhibitors or angiotensin receptor blockers if ACE-inhibitor-intoleran

180 rdial infarction patients suggest a role for angiotensin receptor blockers in patients with heart fai

181 ngiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with heart fai

182 w data exist concerning the effectiveness of angiotensin receptor blockers in this population.

183 ngiotensin-converting enzyme inhibitors, and angiotensin receptor blockers increased by 23%, 57%, 31%

184 ensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers increases the likelihood o

185 w warranted to establish the extent to which angiotensin receptor blockers may provide antiinflammato

186 and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on outcome in patients wit

187 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confide

188 Chronic treatment with angiotensin receptor blockers was associated with better

189 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was indicated in 18.1% of

190 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with well controlled BP an

191 ing angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 4.5 million not recei

192 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and aldosterone antagonis

193 aneurysmal disease, including beta-blockers, angiotensin receptor blockers, and angiotensin-convertin

194 ns, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and beta-blockers, respec

195 th angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium antagonists y

196 s, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers, and diuretics.

197 of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and more sunscreen use in

198 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and P2Y12 antagonists) re

199 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins (combination

200 rs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins after acute m

201 rs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins reduces cardi

202 tency is approximately equivalent to that of angiotensin receptor blockers, angiotensin-converting en

203 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, antiplatelet drugs, beta-

204 used in the clinic AT(1)R antagonist drugs (angiotensin receptor blockers, ARBs, or sartans) at prev

205 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta blockers, calcium ch

206 of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, aldosteron

207 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, aldosteron

208 Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and aldost

209 ns, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, and dual a

210 ns, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, and dual a

211 sed angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, and statin

212 (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, spironolac

213 le angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or both.

214 -blockers, angiotensin-converting inhibitors/angiotensin receptor blockers, statins, diabetic treatme

215 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, which together explained

216 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

217 angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers.

218 of the next generation of beta-blockers and angiotensin receptor blockers.

219 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

220 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

221 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

222 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

223 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

224 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

225 zyme, and synthesis of its inhibitors and of angiotensin receptor blockers.

226 (+) intake and angiotensin converting enzyme/angiotensin receptors blockers Rx.

227 ing angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, beta-blockers, and devic

228 (ACE) inhibitors (1.08, 1.02-1.15, p=0.008), angiotensin-receptor blockers (1.16, 1.07-1.25, p=0.0002

229 nsin-converting-enzyme (ACE) inhibitors with angiotensin-receptor blockers (ARB).

230 Angiotensin-receptor blockers (ARBs) are a widely used d

231 Angiotensin-receptor blockers (ARBs) are effective treat

232 ensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinur

233 The role of angiotensin-receptor blockers (ARBs) in treating patient

234 ensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) reduce cardiovascul

235 tensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) who filled brand-na

236 ensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs), 3-hydroxy-3-methyl

237 allergic myocardial infarction, anaphylaxis, angiotensin-receptor blockers (ARBs), beta-adrenergic bl

238 recent analysis showing increased risk with angiotensin-receptor blockers (ARBs).

239 ean BP reduction 12.9/7.7 mm Hg; p < 0.003), angiotensin-receptor blockers (mean BP reduction 13.3/7.

240 angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers after SAVR for severe AS b

241 angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers after surgical aortic valv

242 For patients with persistent symptoms, angiotensin-receptor blockers and aldosterone antagonist

243 (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers and statins), and adverse

244 (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers and statins), and adverse

245 ACE-inhibitors and angiotensin-receptor blockers remain excellent first lin

246 re angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, alpha-blockers, beta-bloc

247 n, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and beta-adrenergic block

248 irm the beneficial effect of ACE-inhibitors, angiotensin-receptor blockers, and diuretics and/or beta

249 of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta blockers, calcium-ch

250 ng angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, and minera

251 ., angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers,

252 angiotensin-converting-enzyme inhibitors, or angiotensin-receptor blockers.

253 is of unproven value, even beta-blockers and angiotensin-receptor blockers.

254 angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.

255 angiotensin-converting enzyme inhibitors or angiotensin receptor blocking agents 85.3% versus 77.4%

256 sms for sexual dimorphism of regional aortic angiotensin receptor expression and AAA formation are un

257 that in this model, expression of the AT(1b) angiotensin receptor gene in the adrenal gland is upregu

258 Mice lacking AT(1) angiotensin receptors have an impaired capacity to conce

259 ngiotensin system (RAS) and the type I (AT1) angiotensin receptor in essential hypertension, we devel

260 s indicate widespread up-regulation of brain angiotensin receptors in SHR.

261 e findings suggest that activation of type 1 angiotensin receptors in the glomerulus is sufficient to

262 ies suggest that hyperactivation of brain AT angiotensin receptors is a major pathophysiological fact

263 In murine systems, there is a second type 1 angiotensin receptor isoform, AT1B, and its expression i

264 xa11s, GATA6, TGFbeta2, chemokine ligand 12, angiotensin receptor like 1, cytochrome P450, cadherin5,

265 ponent 1, q subcomponent receptor 1 (C1qr1), angiotensin receptor-like 1 (Agtrl1), and vascular endot

266 that are being probed include, among others, angiotensin receptors, matrix metalloproteinases, integr

267 Angiotensin receptor neprilysin inhibition (ARNI) therap

268 icacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), in pat

269 eptide and left atrial size suggest that the angiotensin receptor neprilysin inhibitor LCZ696 may red

270 ioN fracTion (PARAMOUNT) trial, in which the angiotensin receptor neprilysin inhibitor LCZ696 reduced

271 ents with heart failure (HF) treated with an angiotensin receptor neprilysin inhibitor lived longer w

272 The angiotensin receptor neprilysin inhibitor sacubitril/val

273 The angiotensin receptor neprilysin inhibitor sacubitril/val

274 rtality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/val

275 on enrolled in the Prospective comparison of angiotensin receptor neprilysin inhibitor with angiotens

276 Angiotensin receptor neprilysin inhibitors (ARNi), beyon

277 We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with en

278 randomized in the Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With an Angiot

279 Sacubitril/valsartan, a combination angiotensin receptor-neprilysin inhibitor, improves morb

280 GM-HF trial (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] With ACEI [An

281 (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [An

282 PARADIGM-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [An

283 alocorticoid receptor antagonists (MRA), and angiotensin receptor-neprilysin inhibitors (ARNI), have

284 ening in the Prospective Comparison of ARNI (angiotensin-receptor-neprilysin inhibitor) with ACEI (an

285 y, we found that activation of ERK1/2 by the angiotensin receptor occurs via both of these distinct p

286 tration of losartan, which blocks all type 1 angiotensin receptors, reduced markers of kidney disease

287 ystems diacylglycerol produced during type 1 angiotensin receptor signaling can be converted to 2-ara

288 In contrast, the decline in BP with angiotensin receptor subtype 1 (AT1) antagonism and vasc

289 o angiotensin II and a reduction in vascular angiotensin receptor subtype 2 (AT2) expression.

290 th an animal model of PTSD and the selective angiotensin receptor type 1 (AT1) antagonist losartan, w

291 Co-localization of Kv4.3 with angiotensin receptor type 1 and fluorescent resonance en

292 In this complex the angiotensin receptor type 1 associates with the potassiu

293 played decreased fibrosis in response to the angiotensin receptor type 1 blocker losartan showed decr

294 Use of losartan, an angiotensin receptor type 1 blocker used widely in the c

295 ternalization of Kv4.3 in a complex with the angiotensin receptor type 1.

296 t a novel signal transduction complex of the angiotensin receptor type 1.

297 ing enzyme (ACE), angiotensinogen (AGT), and angiotensin receptor type I (AGTR1) have been associated

298 fluorescent protein revealed that Kv4.3 and angiotensin receptor type I are located in close proximi

299 with signaling from other receptors such as angiotensin receptors, which also couple to Gq) appears

300 sential step linking the activation of AT(1) angiotensin receptors with pericyte contraction.